Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis Jennifer Hirshfeld-Cytron, MD, MSCI; Jordan Winter, MD

Size: px
Start display at page:

Download "Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis Jennifer Hirshfeld-Cytron, MD, MSCI; Jordan Winter, MD"

Transcription

1 Research REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis Jennifer Hirshfeld-Cytron, MD, MSCI; Jordan Winter, MD OBJECTIVE: Regret after tubal ligation continues to be a problem. After tubal ligation, couples have the option of tubal surgery or in vitro fertilization (IVF). STUDY DESIGN: Using decision analysis techniques, we compared cost-effectiveness of tubal reanastomosis by tubal type vs tubal surgery or in vitro fertilization (IVF) for 3 separate age groups of women: <35 years of age, 35 to 40 years of age and >40 years of age. Tubal techniques was divided into type A, those with more favorable prognosis because of the likelihood of having a more significant length tube at time of reanastomosis and type B, those with a worse prognosis of success. We incorporated delivery costs to address the impact of high order multiples in IVF. Data were extracted by studies available in the literature. All costs were adjusted to 2012 US dollars. One-way and 2-way sensitivity analyses were performed. RESULTS: The laparoscopic reanastomosis of type A dominated the other groups, because it was more effective and less costly then type B and IVF. However, when women were >40 years old with a history of type B, IVF was favored when its costs were at the lower limit. CONCLUSION: The most cost-effective choice for a woman desiring pregnancy after tubal ligation is laparoscopic reanastomosis after a prior clip or ring tubal ligation for women 40yearsold.Itisalsothemostcosteffective for the oldest cohort, assuming IVF costs are greater than $4500. Key words: cost-effectiveness, decision analysis, in vitro fertilization, multiple gestation, tubal reversal Cite this article as: Hirshfeld-Cytron J, Winter J. Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis. Am J Obstet Gynecol 2013;209:56.e1-6. Currently, 700,000 women have tubal ligation performed every year. 1 The use of long-acting contraception (LARC) has been a major focus within the US. 2 LARC has the distinct advantage of allowing a patient to have highly effective contraception that can be changed in the future. Counseling is essential; a longacting reversible contraception option may be a better choice compared with bilateral tubal ligation in women who are From the Department of Obstetrics and Gynecology, University of Illinois Medical Center at Chicago, Chicago, IL. Received Jan. 22, 2013; revised March 17, 2013; accepted April 8, The authors report no conflict of interest. Presented at the 68th annual meeting of the American Society for Reproductive Medicine, San Diego, CA, Oct , Reprints: Jennifer Hirshfeld-Cytron, MD, MSCI, Department of Obstetrics and Gynecology, University of Illinois Health and Hospitals System, 800 S. Wood St. MC808, Chicago, IL jhirshfeldcytron@gmail.com /$36.00 ª 2013 Mosby, Inc. All rights reserved. not concrete in their decision and especially in younger women in whom the risk of regret is higher. Yet, irreversible contraception such as tubal ligation is still performed to a significant degree. Although women are counseled that tubal ligation is a permanent form of contraception,2-30%ofwomensubsequently regret their decision. 3,4 After tubal ligation, if a woman is interested in future childbearing she can proceed with surgical tubal reanastomosis or in vitro fertilization (IVF). The type of tubal ligation performed can influence the success rates of surgical anastomosis. This is due to the likelihood of having a more substantial remnant tubal length for reanastomosis. For instance, the success rates of tubal reanastomosis as measured by subsequent live birth after a clip or ring placement is estimated at % compared with % success with history of Pomeroy, Parkland, electrocautery, and other modalities. 5-7 Age is also known to be an important prognostic factor with women less than 40 years of age having higher success rates of live birth compared with older women. 8 Thus, when deciding which modality to recommend, practioners have to consider multiple factors. The recommendation for surgery vs IVF has traditionally been based on multiple factors including: age of the women, type of tubal ligation procedure, ovarian reserve, surgical candidacy, other infertility diagnosis, insurance coverage, number of children desired, and others. 8 Recently, an American Society of Reproductive Medicine (ASRM) Committee Opinion concluded that although IVF has a higher per cycle pregnancy rate, tubal anastomosis, with significantly higher cumulative pregnancy rates, is more cost-effective for all woman including those greater than 40 years of age. 8 Interestingly, a retrospective article comparing IVF to tubal anastomosis used in the ASRM recommendation assessed cost-effectiveness in the absence of delivery costs. 9 Therefore, tubal anastomosis was more cost effective than IVF even without considering costs associated with multiple births. The most cost-effective strategy for women with a history of tubal ligation interested in future childbearing remains somewhat uncertain. There are currently neither longitudinal comparative 56.e1 American Journal of Obstetrics & Gynecology JULY 2013

2 Reproductive Endocrinology and Infertility Research TABLE 1 Probability estimates Clinical situation Age range Base case (range) References Successful tubal reanastomosis with A NA 75% (56.6e100%) 5,6,7 Successful tubal reanastomosis with B NA 67.5% (40e74.3%) 5,6,7 Successful live birth with tubal reanastomosis A and B NA 72.5% (18e85%) 5,7,11-15 Live birth rate (singleton) after tubal reanastomosis % (50e100%) Live birth rate (twins) after tubal reanastomosis % (0e2%) Live birth rate (triples or more) after tubal % (0e0.3%) reanastomosis IVF live birth rate singleton % (13e40%) IVF live birth rate twins % (6e24%) IVF live birth rate triplets or more % (0e3%) Live birth rate (singleton) after tubal reanastomosis 35e % (50e100%) Live birth rate (twins) after tubal reanastomosis 35e40 0.9% (0e2%) Live birth rate (triplets) after tubal reanastomosis 35e % (0e0.3%) IVF live birth rate singleton 35e % (10e30%) IVF live birth rate twins 35e40 9.2% (6e24%) IVF live birth rate triplets or more 35e40 1% (0e3%) Live birth rate (singleton) after tubal reanastomosis > % (50e100%) Live birth rate (twins) after tubal reanastomosis > % (0e2%) Live birth rate (triples or more) after tubal > % (0e0.3%) reanastomosis IVF live birth rate singleton > % (5e15%) IVF live birth rate twins >40 4.7% (6e24%) IVF live birth rate triplets or more > % (0e3%) IVF, in vitro fertilization; NA, not available. studies nor randomized trials addressing this, and either would be difficult to accomplish. We sought to compare costeffectiveness between tubal reanastomosis and IVF incorporating the impact of age, type of tubal procedure, and delivery costs to address the impact of multiples with IVF. MATERIALS AND METHODS This study compared the cost-effectiveness of laparoscopic tubal reanastomosis using 2 different types of tubal ligation compared with each other, as well as, IVF. The types of tubal ligation techniques were divided into type A the more favorable prognosis group (ie, clip or ring tubal ligation) because of the likelihood of having a more significant length of tube remaining at the time of reanastomosis and type B the less favorable prognosis group encompassing all other types of tubal ligation (ie, postpartum tubal ligation, electrocautery, Parkland, or unknown type). Both types of tubal ligation reanastomosis were compared with each other and to IVF. Laparoscopic tubal reanastomosis was chosen over open technique in attempts to minimize costs associated with the procedures. The likelihood of patients having a tubal ligation with type Avs B was estimated to be 46.1% and 53.90%, respectively. 10 Probability estimates for a successful reanastomosis and IVF were extracted from published data and were formulated JULY 2013 American Journal of Obstetrics & Gynecology 56.e2

3 Research Reproductive Endocrinology and Infertility into a decision tree comparing types of tubal ligation type A or B vs IVF 5-7,11-18 (Table 1). The average pregnancy following surgery was months, the range within the literature was 2-88 months. Society for Assisted Reproductive Technology (SART) rates were used to estimate live birth rates from assisted reproductive technologies (ART) based on age and risk of multiples was based. 17,18 Only fresh IVF outcomes were considered. Each scenario that used ART was allowed to run a total of four rounds to simulate the number of times insurance would cover attempted pregnancy with IVF in states with state mandatedinsurance. Although insurance companies may cover a different number of cycles depending on their policy and the respective state, we chose to allow our model to run four times to simulate a middle range number of cycles covered in states with mandated insurance. Three separate trees were created to compare patients of the following ages: less than 35 years of age, 35 to 40 years of age, and greater than 40 years of age. The decision tree model was constructed using Tree- Age version 3.5 (Tree Age Software, Williamstown, MA). Costs for tubal reanastomosis and IVF were extrapolated from published data and were adjusted to 2012 US dollars using the medical care component of the Consumer Price Index 13,17,19-24 (Table 2). Studies that described costs were preferred and chosen when available. When only charges were available, they were converted to costs using 0.6 cost-to-charge ratios. Costs were also converted from foreign currency to US dollars with the average exchange rates for that given calendar year. 25 The study also incorporated delivery costs of singleton; twin and multiple births to address the impact of high order multiples with ART. 17 Only direct costs were considered. The effectiveness measure in the analysis was live birth, and the primary cost-effective outcome was the marginal cost (USD) per live birth for each strategy. The primary outcome of the decision analysis is cost per live birth. Ectopic pregnancies are increased in patients with a history of tubal reversal and in TABLE 2 Cost estimates Service Base case (range) Charge or cost Reference LSC tubal $ ($ e ) Cost 13,19,20 reanastamosis Delivery cost singleton $15, Charge 17 Delivery cost twins $58, Charge 17 Delivery cost triplets $169, Charge 17 IVF cycle $10, ($7,363.67e16,015.99/cycle) Charge and cost 13,20-24 All cost expressed in 2012 US dollars; older references were adjusted to 2012 US dollars using the Consumer Price Index. IVF, in vitro fertilization; LSC, laparoscopic. patients that have undergone ART. Ectopic pregnancy is estimated at 2% in the general population and in one study comparing ectopic pregnancy in tubal reanastomosis vs in ART was 6.7% vs 5.6%, respectively. 26 Thus, ectopic gestation is at increased risk for patients in both groups. The most effective and least costly is noted as the dominant strategy in the model. Difference in cost and effectiveness were used to calculate the marginal costs and marginal effectiveness respectively for each model. One-way sensitivity analysis was used to test the model s probability changes and costs, with base cases and ranges derived from published data. When ranges were not available from literature, the range was set at 50% of the case base value. Two-way sensitivity analyses were also conducted. The study was considered exempt by the institutional review board at University of Illinois Medical Center At Chicago. RESULTS Decision trees were formulated for each age group using cost-based estimates. Base-case estimated costs were cheapest for Type A reanastomosis per live birth at every age. It was estimated at $19,300/ live birth a for 35 years old, $23,000/live birth at years old, and $26,200/ live birth for woman greater than 40 years of age. Marginal costs for type B reanastomosis and IVF ranged from $1000e8000. Type A reanastomosis was also more effective per live birth for each age group compared with the other 2 strategies, and thus the dominating or preferred strategy. This was true for all 3 ages using base-case estimates (Table 3). The marginal cost effectiveness (ie, each additional live birth performed with type B tubal reanastomosis and IVF compared with type A tubal reanastomosis) was $58,300 and $30,900, respectively, for the youngest age cohort. In the 35 to 40-year cohort, the marginal cost effectiveness was $111,000 and $44,000 respectively for type B reanastomosis and IVF. Lastly, the marginal cost-effectiveness for the oldest age cohort was $38,400 and $9,540 for type B reanastomosis and IVF, respectively (Table 3). Laparoscopic reanastomosis of a prior clip or ring tubal ligation (type A) dominated the other less favorable (type B) and IVF at every age. In other words, it was more effective and less costly than type B reanastomosis or IVF. Type B reanastomosis also dominated IVF in that it was more effective and less costly. The marginal cost effectiveness estimates when comparing the 2 tubal types are higher values because efficacy is almost equivalent between the 2 tubal types. Because marginal costeffectiveness is calculated by marginal cost divided by marginal effectiveness, the small denominator results in a large estimated cost difference. One-way sensitivity analysis was performed to demonstrate the robustness of the model. When women were older 56.e3 American Journal of Obstetrics & Gynecology JULY 2013

4 Reproductive Endocrinology and Infertility Research TABLE 3 Cost and effectiveness outcomes Strategy Age range Cost Effectiveness Marginal cost Marginal effectiveness Marginal cost/effectiveness Tubal reanastomosis A K Tubal reanastomosis B K K Dominated IVF K K Dominated (30.9K) Tubal reanastomosis A 35e40 23K Tubal reanastomosis B 35e40 25K K Dominated IVF 35e40 31K K Dominated (44K) Tubal reanastomosis A > K Tubal reanastomosis B > K K Dominated IVF > K K Dominated (9.54K) IVF, in vitro fertilization. than 40 and had a history of tubal type B, if the cost of IVF was in the lower limit of the range reported in the literature $4500 (US), then IVF was favored. IVF costs had to be less than reported in the literature (<$3000) for it to be favored over either tubal strategy for the 2 younger cohorts. In addition, when type A strategy was assessed at its lowest pregnancy rate within the range reported FIGURE Two-way sensitivity analysis for the oldest cohort in the literature, and type B was at its highest efficacy rate, then type B was the favored strategy. Of note, both procedures were favored over IVF. In particular for woman less than 35 years of age, type A strategy was favored over type B when subsequent successful pregnancy rates were greater than 80%. Conversely, type B strategy was favored when it had a subsequent pregnancy rate Two-way sensitivity analysis is depicted for women greater than 40 years of age. The analysis of IVF cost and successful singleton live births are compared and the dominant strategy is depicted. Type A tubal reanastomosis dominates for the majority of cases, except when IVF costs become low and/or success of type A is less than 50% in which case type B dominates. IVF, in vitro fertilization. that was greater than 88%. For patients between the ages of years of age, if type A tubal reanastomosis had a successful pregnancy rate of less than 70% then type B was favored when it was greater than 70% successful. Lastly, for the oldest cohort, the cut point at which the strategy type A was no longer favored over type B was at approximately 50% subsequent successful pregnancy rate. Two-way sensitivity analysis was done comparing the 2 types of tubal ligation processes and confirmed the above noted cut-points for each age cohort analyzed (Figure). COMMENT The results of this analysis suggest that the strategy of tubal reversal for patients, with a history of favorable ligation technique, is the most cost-effective. This held true for all age groups. Tubal reversal, regardless of the type of ligation performed, was more cost-effective than IVF at all age groups. When analysis was conducted using tubal reversal, subsequent pregnancy rates at the extremes in the literature, the preferred strategy between the favorable and nonfavorable type ligation techniques varied. In particular, the older a patient was, the lower the cut point in pregnancy rates occurred; more specifically, for woman >40 years of age, tubal reversal success of type A had to be less than 50% for type B to be favored, compared with JULY 2013 American Journal of Obstetrics & Gynecology 56.e4

5 Research Reproductive Endocrinology and Infertility 80% in the youngest cohort. This information can be helpful in individualizing recommendations to particular patients. Either way, both tubal reversal strategies were favored over IVF. It was only for the oldest cohort that IVF was favored over the woman undergoing tubal reversal with a less favorable ligation type. This occurred when IVF costs were at the lowest level reported in the literature, namely $ US dollars. Few decision-analysis of this type have been conducted. Our analysis differed to others conducted, 27 in that it included 3 age groups, differentiated by type of tubal ligation performed and included delivery costs. We believe the incorporation of these variables will assist clinicians in applying the results to individual patients. The inclusion of delivery costs, in particular costs associated with twin and high-order multiples, more clearly define the true costs of ART procedures given that IVF is known to significantly increase the incidence of multiples. Societal cost effectiveness and policy regarding potential insurance coverage of tubal reversal and/or IVF in a woman that has undergone voluntary sterilization need to consider the significant costs related to multiples. 28,29 Limitations of this study should be acknowledged. This study is limited to an examination of the direct medical costs incurred and did not include indirect costs such as lost wages during any of the treatments or childcare. We elected to focus on the direct medical costs because the decision to proceed with a particular algorithm is often dependent on the demands of medical insurance that consider direct costs only. It should be noted the success rates of laparoscopic tubal reanastomosis were taken from those published in the literature and are likely biased by surgeons who are very skilled in the procedure, but that leads to the importance of continued education and practice in this procedure in teaching centers and by practitioners to give patients the best options. In addition, all treatments used are considered minimally invasive procedures with limited recovery time. In particular, we limited our analysis to tubal reversal performed using conventional laparoscopy. Robotic assisted laparoscopic tubal reanastomosis was not incorporated into this cost-effective analysis because of the limited published data for success rates and cost. A recent study showed median difference in costs of the procedures was $1446 between a mini laparotomy vs robotic assisted laparoscopic tubal reanastomosis, however, limited data exists between laparoscopy alone and robotic assisted. 30 Although, under base case assumptions, the tubal reversal strategies appear to be preferred, some may challengethatnotionbecausethecostthatis reasonable for society to bear to produce a live-born remains controversial. Yet, many ART-based decision models have used live birth as the clinical outcome. 21,31-33 Standard effectiveness outcomes such as QALYs (quality adjusted life years) were not used, because their use in certain pregnancy situations can be difficult to interpret and sometimes misleading. 33,34 Furthermore, neonatal outcomes and associated costs were not included in the analysis. The clinical decision between tubal reversal and IVF for patients with history of voluntary sterilization is impacted by many things including: patient age, body mass index, desired number of subsequent children, ovarian reserve markers, partner semen analysis, and arguably physician preference. Ultimately, the true test of superiority of one treatment strategy over another requires a randomized control trial. Conducting a randomized control trial in this situation is unlikely given the cost and feasibility of performing such a study; thus, there is a role for decision analysis in addressing this clinical situation. Although our analysis strongly favors tubal reversal, particularly for those women with a history of clip or ring ligation, this is dependent on highly skilled surgeons to perform these surgeries. Studies cited in this study were from groups with extensive surgical experience. As reproductive endocrinology and infertility training becomes arguably, less focused on surgery, the question exists about who should be performing the reversal. Our results support the continued training of gynecologists in minimally invasive approaches to tubal reversal. - REFERENCES 1. Westhoff C, Davis A. Tubal sterilization: focus on the U.S. experience. Fertil Steril 2000;73: Finer LB, Jerman J, Kavanaugh ML. Changes in use of long acting contraceptive methods. Fertil Steril 2012;98: Chi IC, Jones DB. Incidence, risk factors, and prevention of poststerilization regret in women: an updated international review from an epidemiological perspective. Obstet Gynecol Surv 1994;49: Schmidt JE, Hillis SD, Marchbanks PA, Jeng G, Peterson HB. Requesting information about and obtaining reversal after tubal sterilization: findings from the U.S. collaborative review of sterilization. Fertil Steril 2000;74: Gordts S, Campo R, Puttemans P. Clinical factors determining pregnancy outcome after microsurgical tubal reanastomosis. Fertil Steril 2009;92: Kim JD, Kim KS, Doo JK, Rhyeu CH. A report on 387 cases of microsurgical tubal reversals. Fertil Steril 1997;68: Schepens JJ, Mol BW, Wiegerinck MA, Houterman S, Koks CA. Pregnancy outcomes and prognostic factors from tubal sterilization reversal by sutureless laparoscopical reanastomosis: a retrospective cohort study. Hum Reprod 2011;26: Committee opinion: role of tubal surgery in the era of assisted reproductive technology. Fertil Steril 2012;97: Boeckxstaens A, Devroey P, Collins J, Tournaye H. Getting pregnant after tubal sterilization: surgical reversal or IVF? Hum Reprod 2007;22: Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-8; discussion Deffieux X, Morin Surroca M, Faivre E, Pages F, Fernandez H, Gervaise A. Tubal anastomosis after tubal sterilization: a review. Arch Gynecol Obstet 2011;283: Bissonnette F, Lapensee L, Bouzayen R. Outpatient laparoscopic tubal anastomosis and subsequent fertility. Fertil Steril 1999;72: Tan HH, Loh SF. Microsurgical reversal of sterilisation is this still clinically relevant today? Ann Acad Med, Singapore 2010;39: Kaloo P, Cooper M. Fertility outcomes following laparoscopic tubal re-anastomosis post tubal sterilisation. Austr N Z J Obstet Gynaecol 2002;42: Petrucco OM, Silber SJ, Chamberlain SL, Warnes GM, Davies M. Live birth following day surgery reversal of female sterilisation in women older than 40 years: a realistic option in Australia? Med J Austr 2007;187: Gomel V. Reversal of tubal sterilization versus IVF in the era of assisted reproductive technology: a clinical dilemma. Reprod Biomed Online 2007;15: e5 American Journal of Obstetrics & Gynecology JULY 2013

6 Reproductive Endocrinology and Infertility Research 17. Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF Jr. The economic impact of multiple-gestation pregnancies and the contribution of assistedreproduction techniques to their incidence. New Engl J Med 1994;331: Society for Assisted Reproductive Technologies. Clinical summary report. Available at: Accessed April 1, Schippert C, Hille U, Bassler C, Soergel P, Hollwitz B, Garcia-Rocha GJ. Organ-preserving and reconstructive microsurgery of the fallopian tubes in tubal infertility: still an alternative to in vitro fertilization (IVF). J Reconstr Microsurg 2010;26: Hawkins J, Dube D, Kaplow M, Tulandi T. Cost analysis of tubal anastomosis by laparoscopy and by laparotomy. J Am Assoc Gynecol Laparosc 2002;9: Hirshfeld-Cytron JE, van Loenerdensloot L, Mol BW, et al. Cost-effective analysis of oocyte cryopreservation-stunning similarities but differences remain. Hum Reprod 2012;27: Collins J. An international survey of the health economics of IVF and ICSI. Hum Reprod Update 2002;8: Neumann PJ, Gharib SD, Weinstein MC. The cost of a successful delivery with in vitro fertilization. New Engl J Med 1994;331: De Sutter P, Gerris J, Dhont M. A healtheconomic decision-analytic model comparing double with single embryo transfer in IVF/ICSI. Hum Reprod 2002;17: Yahoo finance. Currency converter. Available at #from-usd;to¼eur;amt¼1. Accessed April 1, Schippert C, Soergel P, Staboulidou L, et al. The risk of ectopic pregnancy following tubal reconstructive microsurgery and assisted reproductive technology procedures. Arch Gynecol Obstet 2012;285: Alford CE CJ, Segars JH, Armstrong AY. Cost analysis of in vitro fertilization (IVF) versus bilateral (BTA) to achieve a live birth. Fertil Steril 2010;94:S Adashi EY, Barri PN, Berkowitz R, et al. Infertility therapy-associated multiple pregnancies (births): an ongoing epidemic. Reprod Biomed Online 2003;7: Peterson CM, Reading JC, Hatasaka HH, et al. Use of outcomes-based data in reducing high-order multiple pregnancies: the role of age, diagnosis, and embryo score. Fertil Steril 2004;81: Rodgers AK, Goldberg JM, Hammel JP, Falcone T. Tubal anastomosis by robotic compared with outpatient minilapartomy. Obstet Gynecol 2007: (level II-2). 31. Griffiths A, Dyer SM, Lord SJ, Pardy C, Fraser IS, Eckermann S. A cost-effectiveness analysis of in-vitro fertilization by maternal age and number of treatment attempts. Hum Reprod;25: Jungheim ES, Odibo AO. Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents. Fertil Steril;94: Kansal-Kalra S, Milad MP, Grobman WA. In vitro fertilization (IVF) versus gonadotropins followed by IVF as treatment for primary infertility: a cost-based decision analysis. Fertil Steril 2005;84: Ganiats TG. Justifying prenatal screening and genetic amniocentesis programs by costeffectiveness analyses: a re-evaluation. Med Decis Making 1996;16: JULY 2013 American Journal of Obstetrics & Gynecology 56.e6

Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao.

Welcome to chapter 2. The following chapter is called Indications For IVF. The author is Dr Kamini A. Rao. Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao. The indications for an IVF treatment have increased since the birth of the first IVF baby. The

More information

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Insurance Coverage for Infertility Treatment Revised November 2004 Infertility is a condition

More information

Fast Track to IVF. Objectives

Fast Track to IVF. Objectives Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.

More information

IVF SUCCESS RATES. Cancellation Rates. Under Age 35: 0% cancellations, national average 7.1% Age 35 37: 2.0% cancellations national average 10.

IVF SUCCESS RATES. Cancellation Rates. Under Age 35: 0% cancellations, national average 7.1% Age 35 37: 2.0% cancellations national average 10. IVF SUCCESS RATES Program for Asst. Reproduction at Carolinas Medical Center, Charlotte, NC Number of ART cycles and transfers in 2009: 249 42.5 % 41.4 % 38.5 % 31.7 % Started 80 IVF cycles resulting in

More information

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance.

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance. INSURANCE DIVISION OF INSURANCE Actuarial Services Benefit Standards for Infertility Coverage Proposed New Rules: N.J.A.C. 11:4-54 Authorized By: Holly C. Bakke, Commissioner, Department of Banking and

More information

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register 1 Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register Joanne Gunby, M.Sc. CARTR Co-ordinator Email: gunbyj@mcmaster.ca Supported by the IVF Directors Group of

More information

Management fertility sparing degli endometriomi Errico Zupi

Management fertility sparing degli endometriomi Errico Zupi Management fertility sparing degli endometriomi Errico Zupi Università Tor Vergata Roma Management of endometrioma Pain Infertility Surgical treatment Medical treatment Infertility clinic Both medical

More information

Ehlers-Danlos Syndrome Fertility Issues. Objectives

Ehlers-Danlos Syndrome Fertility Issues. Objectives Ehlers-Danlos Syndrome Fertility Issues Baltimore Inner Harbor Independence Day Brad Hurst, M.D. Professor Reproductive Endocrinology Carolinas Medical Center - Charlotte, North Carolina Objectives Determine

More information

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies OHTAC Recommendation In Vitro Fertilization and Multiple Pregnancies October 19, 2006 The Ontario Health Technology Advisory Committee (OHTAC) met on October 19, 2006 and reviewed the health technology

More information

Burton VanderLaan 1,3, Vishvanath Karande 2, Carol Krohm 1, Randy Morris 2, Donna Pratt 2 and Norbert Gleicher 2,4

Burton VanderLaan 1,3, Vishvanath Karande 2, Carol Krohm 1, Randy Morris 2, Donna Pratt 2 and Norbert Gleicher 2,4 Human Reproduction vol.13 no.5 pp.1200 1205, 1998 Cost considerations with infertility therapy: outcome and cost comparison between health maintenance organization and preferred provider organization care

More information

European IVF Monitoring (EIM) Year: 2008

European IVF Monitoring (EIM) Year: 2008 European IVF Monitoring (EIM) Year: 2008 Name of country POLAND Name and full address of contact person. professor Rafal Kurzawa MD PhD Fertility and Sterility Special Interest Group Polish Gynaecological

More information

Fertility Facts and Figures 2008

Fertility Facts and Figures 2008 Fertility Facts and Figures 2008 Contents About these statistics... 2 Accessing our data... 2 The scale of fertility problems... 3 Treatment abroad... 3 Contacts regarding this publication... 3 Latest

More information

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although

More information

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Sykes D, Out H J, Palmer S J, van Loon J Record Status This is a critical abstract of an economic evaluation that

More information

Laparoscopic management of endometriosis in infertile women and outcome

Laparoscopic management of endometriosis in infertile women and outcome International Journal of Reproduction, Contraception, Obstetrics and Gynecology Sahu L et al. Int J Reprod Contracept Obstet Gynecol. 2013 Jun;2(2):177-181 www.ijrcog.org pissn 2320-1770 eissn 2320-1789

More information

European IVF Monitoring (EIM) Year: 2010

European IVF Monitoring (EIM) Year: 2010 European IVF Monitoring (EIM) Year: 2010 Name of country: Poland Name and full address of contact person: Professor Rafal Kurzawa, MD PhD Fertility and Sterility Special Interest Group Polish Gynaecological

More information

Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES

Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES Standardising Access Criteria to NHS Fertility Treatment FOR COMMISSIONERS OF FERTILITY SERVICES Status of the document This document offers guidance to help PCTs move towards more equitable provision

More information

Assisted Reproductive Technologies at IGO

Assisted Reproductive Technologies at IGO 9339 Genesee Avenue, Suite 220 San Diego, CA 92121 858 455 7520 Assisted Reproductive Technologies at IGO Although IGO no longer operates an IVF laboratory or program as such, we work closely with area

More information

IVF OVERVIEW. Tracy Telles, M.D.

IVF OVERVIEW. Tracy Telles, M.D. IVF OVERVIEW By Tracy Telles, M.D. Dr. Hendler: Hello and welcome to KP Healthcast. I m your host Dr. Peter Hendler and today our guest is Dr. Tracy Telles. Dr. Telles is an IVF physician in Kaiser Walnut

More information

COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY

COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY COVENTRY HEALTH CARE OF ILLINOIS, INC. COVENTRY HEALTH CARE OF MISSOURI, INC. Medical Management Policy and Procedure PROPRIETARY Policy: Infertility Evaluation and Treatment Number: MM 1306 Date Effective:

More information

Authors: Melissa Logsdon, M.P.H., Emily M. Godfrey, M.D., M.P.H., Arden Handler,

Authors: Melissa Logsdon, M.P.H., Emily M. Godfrey, M.D., M.P.H., Arden Handler, Authors: Melissa Logsdon, M.P.H., Emily M. Godfrey, M.D., M.P.H., Arden Handler, DrPH ABSTRACT Purpose: To determine women s preferences for the location of early abortion services. Description: Between

More information

Money-back guarantee,

Money-back guarantee, Money-back IVF guarantees: weighing the pros and cons By David Adamson, MD IVF refund programs have been around for more than a decade and patients seem to like them. But critics question whether such

More information

Areas of Concern. Reproductive Ethics: Issues &

Areas of Concern. Reproductive Ethics: Issues & Reproductive Ethics: Issues & Areas of Concern Conception Control: under what conditions is conception control in harmony with a Christian ethic? Genetic Screening & Counseling: under what conditions should

More information

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups File name: Infertility Services File code: UM.REPRO.01 Last Review: 02/2016

More information

Clinical Policy Committee

Clinical Policy Committee Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment

More information

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate.

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate. University Hospitals Coventry and Warwickshire NHS Trust Centre for Reproductive Medicine We Care. We Achieve. We Innovate. Introduction We were the first NHS Hospital in the West Midlands to set up a

More information

Mandated Health Insurance Benefits and the Utilization and Outcomes of Infertility Treatments. M. Kate Bundorf Melinda Henne Laurence Baker

Mandated Health Insurance Benefits and the Utilization and Outcomes of Infertility Treatments. M. Kate Bundorf Melinda Henne Laurence Baker Mandated Health Insurance Benefits and the Utilization and Outcomes of Infertility Treatments M. Kate Bundorf Melinda Henne Laurence Baker January, 2007 Abstract: During the last two decades, the treatment

More information

How To Get A Refund On An Ivf Cycle

How To Get A Refund On An Ivf Cycle 100% IVF Refund Program Community Hospital North Clearvista Dr. N Dr. David Carnovale and Dr. Jeffrey Boldt, along with everyone at Community Reproductive Endocrinology, are committed to providing you

More information

Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery

Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery The Condition: Early Stage Gynecologic Cancer A variety of gynecologic

More information

Insurance Reimbursement for Post-Pregnancy Long-Acting Reversible Contraception (LARC) Background Benefits of LARC

Insurance Reimbursement for Post-Pregnancy Long-Acting Reversible Contraception (LARC) Background Benefits of LARC Insurance Reimbursement for Post-Pregnancy Long-Acting Reversible Contraception (LARC) Shandhini Raidoo MD, Bliss Kaneshiro MD, MPH, Mary Tschann MPH, Reni Soon MD, MPH, Emmakate Friedlander MD, Jennifer

More information

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Page 1 of 6 AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Age has a profound effect on female fertility. This is common knowledge,

More information

Ethical issues in assisted reproductive technologies. Effy Vayena

Ethical issues in assisted reproductive technologies. Effy Vayena Ethical issues in assisted reproductive technologies Effy Vayena Assisted Reproductive Technologies (ART) All treatments or procedures that include the in vitro handling of human oocytes and human sperm

More information

Illinois Insurance Facts Illinois Department of Insurance

Illinois Insurance Facts Illinois Department of Insurance Illinois Insurance Facts Illinois Department of Insurance Insurance Coverage for Infertility Treatment Revised December 2014 Note: This information was developed to provide consumers with general information

More information

Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register

Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register Joanne Gunby, M.Sc., a Francxois Bissonnette, M.D., b Clifford Librach, M.D., c

More information

Crohn's disease and pregnancy.

Crohn's disease and pregnancy. Gut, 1984, 25, 52-56 Crohn's disease and pregnancy. R KHOSLA, C P WILLOUGHBY, AND D P JEWELL From the Gastroenterology Unit, Radcliffe Infirmary, Oxford SUMMARY Infertility and the outcome of pregnancy

More information

Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy Statement

Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy Statement ATTENTION This Policy was reaffirmed by the ACPM Board of Regents on 1/31/2005 and is effective through 1/31/2010. Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine

More information

Endometriosis, Fertility and Pregnancy

Endometriosis, Fertility and Pregnancy This leaflet covers endometriosis and fertility. It provides information for women who have been diagnosed with endometriosis who would like to know if and how this can affect their fertility, and for

More information

Specialists In Reproductive Medicine & Surgery, P.A.

Specialists In Reproductive Medicine & Surgery, P.A. Specialists In Reproductive Medicine & Surgery, P.A. Craig R. Sweet, M.D. www.dreamababy.com Fertility@DreamABaby.com Excellence, Experience & Ethics Endometriosis Awareness Week/Month Common Questions

More information

FREEDOM OF INFORMATION ACT 2000 Birmingham CrossCity CCG Ref: FOI/002790 IVF Funding Policy

FREEDOM OF INFORMATION ACT 2000 Birmingham CrossCity CCG Ref: FOI/002790 IVF Funding Policy Our Ref: FOI/002790 08 th August 2014 Bartholomew House 1 st Floor 142 Hagley Road Birmingham B16 9PA www.bhamcrosscityccg.nhs.uk Email: bham.crosscity@nhs.net Tel. 0121 255 0700 FREEDOM OF INFORMATION

More information

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan Research and Reviews Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan JMAJ 52(1): 29 33, 2009 Kaoru YANAGIDA* 1 Abstract The three basic pillars of fertility

More information

Infertility Treatment, ART and IUI Procedures and Delivery. Outcomes: How Important is Selection? 1

Infertility Treatment, ART and IUI Procedures and Delivery. Outcomes: How Important is Selection? 1 Infertility Treatment, ART and IUI Procedures and Delivery Outcomes: How Important is Selection? 1 Pooja G. Mookim 2, Randall P. Ellis 2, Ariella Kahn-Lang 3 April 20, 2010 Abstract: High infertility levels

More information

Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer

Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive

More information

SUBSEROSAL FIBROIDS TREATMENT

SUBSEROSAL FIBROIDS TREATMENT INTRODUCTION Uterine fibroids, also known as leiomyomas, are the most common pelvic mass found in women. Fibroids are benign tumors that arise from the uterine muscular tissue (myometrium). They occur

More information

Female sterilization is one of the most common

Female sterilization is one of the most common A Clinical and Medico-Legal Review of Tubal Ligation in Canada Paul Martyn, FRCSC, FRCOG, FRANZCOG, 1 Valerie Prather, LLB 2 1 University of Calgary, Foothills Medical Centre, Calgary AB 2 Bennett Jones

More information

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal

More information

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile?

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile? FERTILITY AND AGE Introduction Delaying pregnancy is a common choice for women in today's society. The number of women in their late 30s and 40s attempting pregnancy and having babies has increased in

More information

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic.

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. Australia s National Infertility Network How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. updated 26 05 2015 20 The information contained here is

More information

Risks and complications of assisted conception

Risks and complications of assisted conception Risks and complications of assisted conception August 005 Richard Kennedy British Fertility Society Factsheet www.fertility.org.uk No medical treatment is entirely free from risk and infertility treatment

More information

Welcome to Cartersville Ob/Gyn Associates.

Welcome to Cartersville Ob/Gyn Associates. Welcome to Cartersville Ob/Gyn Associates. We are a full-service Ob/Gyn practice, delivering women the exceptional care, medical expertise, compassion and support they deserve through every life cycle

More information

Testimony of Anne Davis, MD, MPH. Medical Director. September 12, 2008

Testimony of Anne Davis, MD, MPH. Medical Director. September 12, 2008 Testimony of Anne Davis, MD, MPH Medical Director Physicians for Reproductive Choice and Health Before the President s Council on Bioethics September 12, 2008 My name is Dr. Anne Davis, and I am an Associate

More information

Guidelines for the Number of Embryos to Transfer Following In Vitro Fertilization

Guidelines for the Number of Embryos to Transfer Following In Vitro Fertilization JOINT SOGC CFAS GUIDELINE No 182, September 2006 Guidelines for the Number of Embryos to Transfer Following In Vitro Fertilization This guideline was reviewed by the Reproductive Endocrinology and Infertility

More information

Outline. Objective(s) Background. Methods. Results. Discussion. Questions

Outline. Objective(s) Background. Methods. Results. Discussion. Questions Outline Objective(s) Background Methods Results Discussion Questions Objectives To evaluate if psychological stress varies with the phase of in vitro fertilization treatment To determine if socio-demographic

More information

$100 Individual. Deductible

$100 Individual. Deductible PLAN FEATURES Deductible $100 Individual (per calendar year) $200 Family Unless otherwise indicated, the deductible must be met prior to benefits being payable. Member cost sharing for certain services,

More information

December 4, 2014 Rebecca Johnson, MD Mary Bridge Hospital Tacoma, WA USA

December 4, 2014 Rebecca Johnson, MD Mary Bridge Hospital Tacoma, WA USA Fertility preservation for AYAs December 4, 2014 Rebecca Johnson, MD Mary Bridge Hospital Tacoma, WA USA Aims Guidelines Barriers to implementation Assessment of risk Methods of preserving fertility Optimising

More information

A single center experience with 1000 consecutive cases of multifetal pregnancy reduction

A single center experience with 1000 consecutive cases of multifetal pregnancy reduction A single center experience with 1000 consecutive cases of multifetal pregnancy reduction Joanne Stone, MD, Keith Eddleman, MD, Lauren Lynch, MD, and Richard L. Berkowitz, MD New York, NY, and San Juan,

More information

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 RECIPIENT COUPLE INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION

More information

Considering Endometriosis Surgery? Learn about minimally invasive da Vinci Surgery

Considering Endometriosis Surgery? Learn about minimally invasive da Vinci Surgery Considering Endometriosis Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Endometriosis Endometriosis is a condition in which the tissue that lines your uterus (the endometrium)

More information

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Preimplantation Genetic Diagnosis (PGD) in Western Australia Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome

More information

RYAN G. STEWARD, M.D. HOUSTON FERTILITY INSTITUTE MEDICAL CENTER 713.796.9888 WOODLANDS 281.681.0480 CORPORATE 281.357.1881

RYAN G. STEWARD, M.D. HOUSTON FERTILITY INSTITUTE MEDICAL CENTER 713.796.9888 WOODLANDS 281.681.0480 CORPORATE 281.357.1881 RYAN G. STEWARD, M.D. HOUSTON FERTILITY INSTITUTE MEDICAL CENTER 713.796.9888 WOODLANDS 281.681.0480 CORPORATE 281.357.1881 CERTIFICATION Obstetrics and Gynecology (ABOG), December 2012 LICENSURE Texas,

More information

in vitro Fertilization (IVF)

in vitro Fertilization (IVF) Should an age limit be imposed on in vitro fertilization? Amanda Caster, Rong Hu, John Brothers II, and Barry Sexton Bioengineering and Bioinformatics Summer Institute 2005 University of Pittsburgh, Carnegie

More information

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services.

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services. East Midlands CCGs Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services April 2014 CONTENTS Page 1. INTRODUCTION 3 2. GENERAL

More information

OBGYN Orientation & Billing Guide 9/22/2014

OBGYN Orientation & Billing Guide 9/22/2014 OBGYN Orientation & Billing Guide 2014 Welcome to Magnolia Health! We thank you for being part of or considering Magnolia s network of participating providers, hospitals, and other healthcare professionals.

More information

Current status of assisted reproductive technology in Korea, 2009

Current status of assisted reproductive technology in Korea, 2009 Review Obstet Gynecol Sci 2013;56(6):353-361 http://dx.doi.org/10.5468/ogs.2013.56.6.353 pissn 2287-8572 eissn 2287-8580 Current status of assisted reproductive technology in Korea, 2009 Committee for

More information

Center for Women s Reproductive Care at Columbia University

Center for Women s Reproductive Care at Columbia University Center for Women s Reproductive Care at Columbia University Oocyte Recipients Greetings, Thank you for your interest in the Center for Women s Reproductive Care at Columbia University. We hope that the

More information

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA Table of Contents 1.

More information

HOW IS OVARIAN RESERVE ASSESSED?

HOW IS OVARIAN RESERVE ASSESSED? HOW IS OVARIAN RESERVE ASSESSED? The majority of indicators we have to assess OR assess egg quantity rather than egg quality and these two do not always go hand in hand. No individual test is a perfect

More information

Clinical Policy Title: Home uterine activity monitoring

Clinical Policy Title: Home uterine activity monitoring Clinical Policy Title: Home uterine activity monitoring Clinical Policy Number: 12.01.01 Effective Date: August 19, 2015 Initial Review Date: July 17, 2013 Most Recent Review Date: July 15, 2015 Next Review

More information

Can In Vitro Fertilization enhance fertility in Europe? A scenario study

Can In Vitro Fertilization enhance fertility in Europe? A scenario study Can In Vitro Fertilization enhance fertility in Europe? A scenario study Gijs Beets 3 On behalf of Egbert te Velde 4, J. Dik F. Habbema 1, Marinus J.C. Eijkemans 1, and Geeta Nargund 2 1 Department of

More information

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened Fertility Policy 1 SUMMARY This policy is intended to support individuals and couples who want to become parents but who have a possible pathological problem (physical or psychological) leading to them

More information

Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota

Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota Carol Ludowese, MS, CGC Certified Genetic Counselor HDSA Center of Excellence at Hennepin County Medical Center Minneapolis, Minnesota The information provided by speakers in workshops, forums, sharing/networking

More information

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES We, the undersigned, as patient and partner understand that we will be undergoing one or more procedures

More information

THE MITRE CORPORATION PPO High Deductible Plan with a Health Saving Account (HSA)

THE MITRE CORPORATION PPO High Deductible Plan with a Health Saving Account (HSA) THE MITRE CORPORATION PPO High Deductible Plan with a Health Saving Account (HSA) Effective Date: 01-01-2016 PLAN FEATURES Annual Deductible $1,500 Employee $3,000 Employee $3,000 Employee + 1 Dependent

More information

Aetna HealthFund Health Reimbursement Account Plan (Aetna HealthFund Open Access Managed Choice POS II )

Aetna HealthFund Health Reimbursement Account Plan (Aetna HealthFund Open Access Managed Choice POS II ) Health Fund The Health Fund amount reflected is on a per calendar year basis. If you do not use the entire fund by 12/31/2015, it will be moved into a Limited-Purpose Flexible Spending Account. Health

More information

In Vitro Fertilization and Multiple Pregnancies

In Vitro Fertilization and Multiple Pregnancies Ontario Health Technology Assessment Series 2006; Vol. 6, No. 18 In Vitro Fertilization and Multiple Pregnancies An Evidence-Based Analysis October 2006 Medical Advisory Secretariat Ministry of Health

More information

Maternity Care Primary C-Section Rate Specifications 2014 (07/01/2013 to 06/30/2014 Dates of Service)

Maternity Care Primary C-Section Rate Specifications 2014 (07/01/2013 to 06/30/2014 Dates of Service) Summary of Changes Denominator Changes: Two additions were made to the denominator criteria. The denominator was changed to include patients who had: a vertex position delivery AND a term pregnancy of

More information

Consent for Frozen Donor Oocyte In Vitro Fertilization and Embryo Transfer (Recipient)

Consent for Frozen Donor Oocyte In Vitro Fertilization and Embryo Transfer (Recipient) Name of Patient: Name of Partner: We, the Patient and Partner (if applicable) named above, are each over the age of twenty-one (21) years. By our signatures below, I/we request and authorize the performance

More information

$6,350 Individual $12,700 Individual

$6,350 Individual $12,700 Individual PLAN FEATURES IN-NETWORK OUT-OF-NETWORK Deductible $5,000 Individual $10,000 Individual $10,000 Family $20,000 Family All covered expenses accumulate separately toward the preferred or non-preferred Deductible.

More information

Pre-implantation Genetic Diagnosis (PGD)

Pre-implantation Genetic Diagnosis (PGD) Saint Mary s Hospital Department of Genetic Medicine Saint Mary s Hospital Pre-implantation Genetic Diagnosis (PGD) Information For Patients What is PGD? Pre-implantation genetic diagnosis (PGD) is a specialised

More information

CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM

CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM I, after consultation with my physician, request to participate in the In Vitro Fertilization (IVF)-Embryo Transfer (ET) procedures

More information

All you need to know about Endometriosis. Nordica Fertility Centre, Lagos, Asaba, Abuja

All you need to know about Endometriosis. Nordica Fertility Centre, Lagos, Asaba, Abuja All you need to know about Endometriosis October, 2015 About The Author Nordica Lagos Fertility Centre is one of Nigeria's leading centres for world class Assisted Reproductive Services, with comfort centres

More information

IVF Waiting Times in Scotland

IVF Waiting Times in Scotland IVF Waiting Times in Scotland Quarter ending 31 March 2016 Publication date 31 May 2016 An Official Statistics Publication for Scotland Key Points The Scottish Government have set a target that at least

More information

PREFERRED CARE. All covered expenses, including prescription drugs, accumulate toward both the preferred and non-preferred Payment Limit.

PREFERRED CARE. All covered expenses, including prescription drugs, accumulate toward both the preferred and non-preferred Payment Limit. PLAN FEATURES Deductible (per plan year) $300 Individual $300 Individual None Family None Family All covered expenses, excluding prescription drugs, accumulate toward both the preferred and non-preferred

More information

Health disparities and infertility: impacts of state-level insurance mandates

Health disparities and infertility: impacts of state-level insurance mandates Health disparities and infertility: impacts of state-level insurance mandates Marianne Bitler, Ph.D., a and Lucie Schmidt, Ph.D. b a Public Policy Institute of California, San Francisco, California, and

More information

AUSTRALIA AND NEW ZEALAND FACTSHEET

AUSTRALIA AND NEW ZEALAND FACTSHEET AUSTRALIA AND NEW ZEALAND FACTSHEET What is Stillbirth? In Australia and New Zealand, stillbirth is the death of a baby before or during birth, from the 20 th week of pregnancy onwards, or 400 grams birthweight.

More information

MECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA

MECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility Awareness-Based Methods Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility awareness helps couples understand how to avoid pregnancy or how to become pregnant.

More information

PLAN DESIGN AND BENEFITS - Tx OAMC 2500 08 PREFERRED CARE

PLAN DESIGN AND BENEFITS - Tx OAMC 2500 08 PREFERRED CARE PLAN FEATURES Deductible (per calendar year) $2,500 Individual $5,000 Individual $7,500 3 Individuals per $15,000 3 Individuals per Unless otherwise indicated, the Deductible must be met prior to benefits

More information

PARTICIPATING PROVIDERS / REFERRED Deductible (per calendar year)

PARTICIPATING PROVIDERS / REFERRED Deductible (per calendar year) Your HMO Plan Primary Care Physician - You choose a Primary Care Physician. The Aetna HMO Deductible provider network gives you access to a wide selection of Primary Care Physicians ( PCP's) and Specialists

More information

100% Percentage at which the Fund will reimburse Fund Administration

100% Percentage at which the Fund will reimburse Fund Administration FUND FEATURES HealthFund Amount $500 Employee $1,000 Employee + 1 Dependent $1,000 Employee + 2 Dependents $1,000 Family Amount contributed to the Fund by the employer Fund amount reflected is on a per

More information

California PCP Selected* Not Applicable

California PCP Selected* Not Applicable PLAN FEATURES Deductible (per calendar ) Member Coinsurance * Not Applicable ** Not Applicable Copay Maximum (per calendar ) $3,000 per Individual $6,000 per Family All member copays accumulate toward

More information

Understanding Surrogacy Costs

Understanding Surrogacy Costs Understanding Surrogacy Costs Determining the cost of your surrogacy arrangement can be challenging. We estimated that Abundant Life s typical surrogate birth will cost between $43,000 $70,000 USD depending

More information

Original Article Infertility evaluation via laparoscopy and hysteroscopy after conservative treatment for tubal pregnancy

Original Article Infertility evaluation via laparoscopy and hysteroscopy after conservative treatment for tubal pregnancy Int J Clin Exp Med 2014;7(10):3556-3561 www.ijcem.com /ISSN:1940-5901/IJCEM0001974 Original Article Infertility evaluation via laparoscopy and hysteroscopy after conservative treatment for tubal pregnancy

More information

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014 East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception December 2014 1 1. Introduction This policy sets out the entitlement and service that will

More information

Clinical Studies Abstract Booklet

Clinical Studies Abstract Booklet Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January

More information

Preimplantation Genetic Diagnosis. Evaluation for single gene disorders

Preimplantation Genetic Diagnosis. Evaluation for single gene disorders Preimplantation Genetic Diagnosis Evaluation for single gene disorders What is Preimplantation Genetic Diagnosis? Preimplantation genetic diagnosis or PGD is a technology that allows genetic testing of

More information

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Dr Niel Senewirathne Senior Consultant of Obstetrician & Gynaecologist De zoyza Maternity Hospita 1 ART - IVF & ICSI 2 Infertility No pregnancy

More information

Topic: Male Factor Infertility

Topic: Male Factor Infertility Topic: Male Factor Infertility Topic Overview: Male Factor Infertility Comparisons of pregnancy rates at insemination based on total motile sperm counts from the 1999 and 21 World Health Organization (WHO)

More information

Assisted reproductive technology in Australia and New Zealand 2010

Assisted reproductive technology in Australia and New Zealand 2010 Assisted reproductive technology in Australia and New Zealand 2010 ASSISTED REPRODUCTION SERIES Number 16 Assisted reproductive technology in Australia and New Zealand 2010 Alan Macaldowie Yueping A Wang

More information

Emmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA

Emmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA American Journal of Obstetrics and Gynecology (2006) 194, 1696 701 www.ajog.org Thorough sonographic oocyte retrieval during in vitro fertilization produces results similar to ovarian wedge resection in

More information

Tower Hamlets CCG Fertility policy

Tower Hamlets CCG Fertility policy Tower Hamlets CCG Fertility policy Approved December 2014 Introduction Tower Hamlets CCG is responsible for commissioning a range of health services including hospital, mental health and community services

More information

Elective Single Embryo Transfer Following In Vitro Fertilization

Elective Single Embryo Transfer Following In Vitro Fertilization JOINT SOGC CFAS CLINICAL PRACTICE GUIDELINE No. 241, April 2010 Elective Single Embryo Transfer Following In Vitro Fertilization This clinical practice guideline has been prepared by the Joint Society

More information